B of A Securities Downgrades BioXcel Therapeutics to Underperform, Lowers Price Target to $0.25

Benzinga · 01/07 17:43
B of A Securities analyst Geoff Meacham downgrades BioXcel Therapeutics (NASDAQ:BTAI) from Buy to Underperform and lowers the price target from $7 to $0.25.